Classical psychedelics like psilocybin and LSD are among the least physically toxic recreational substances known, but they carry real psychological risks that depend heavily on the person, the setting, and what’s actually in the drug. The short answer is that psychedelics are unlikely to damage your body or cause addiction, but they can trigger serious psychiatric episodes in vulnerable people and produce frightening experiences that leave lasting anxiety.
Physical Toxicity Is Extremely Low
No lethal dose of psilocybin or LSD has been established in humans. To put psilocybin’s toxicity in practical terms: based on animal studies, a 60-kilogram person would need to eat roughly 17 kilograms of fresh mushrooms to reach a potentially fatal dose. That’s about 37 pounds. For LSD, the theoretical lethal dose is estimated at around 400 times the maximum dose used in therapeutic settings, and only two probable deaths from LSD overdose itself have ever been documented in the medical literature. Deaths associated with LSD have almost always involved accidents, violence, or police restraint during a bad experience, not the drug’s direct effect on the body.
That said, psychedelics are not completely inert. Psilocybin does have cardiovascular effects worth knowing about. In clinical trials, a moderate-to-high dose of psilocybin temporarily raised systolic blood pressure by roughly 20 to 28 points and heart rate by about 11 to 19 beats per minute above baseline. LSD produces a similar bump. These increases are comparable to moderate exercise and resolve within hours, but they matter if you have an underlying heart condition or uncontrolled high blood pressure. The effects are dose-dependent: higher doses produce bigger spikes.
Addiction Risk Is Minimal
Psychedelics are not addictive in the way most people understand the word. Animal and human studies consistently show low abuse potential and no physical dependence. Your body builds tolerance to psilocybin and LSD rapidly, sometimes within days, which makes compulsive daily use essentially self-limiting. A formal review of psilocybin’s abuse potential concluded it warrants less restrictive scheduling than most controlled substances, comparable to drugs like benzodiazepines rather than heroin or cocaine. That doesn’t mean people never misuse psychedelics, but the pattern of escalating, compulsive use seen with stimulants, opioids, or alcohol is largely absent.
Psychological Risks Are the Real Concern
The biggest danger psychedelics pose is to your mind, not your body. In a large survey of psychedelic users, about 41% reported never having a challenging or distressing experience. But among those who did, 57% reported at least one enduring symptom afterward, with anxiety being the most common. Notably, most psychedelic users in the same survey still agreed they were glad they had used the drugs, suggesting many people ultimately view even difficult experiences as worthwhile. That said, a minority of people have genuinely harmful outcomes.
The most serious psychological risk is triggering psychosis. In uncontrolled studies that included people with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those who experienced psychedelic-induced psychosis, about 13% later developed schizophrenia. The risk is highest for people with a personal or family history of psychotic disorders or bipolar disorder. Psychedelic use has been specifically linked to an increased risk of manic episodes with psychotic features in people with bipolar vulnerability. If schizophrenia, schizoaffective disorder, or bipolar disorder runs in your family, psychedelics carry a meaningful risk that most researchers consider a clear contraindication.
Hallucinogen Persisting Perception Disorder
A small number of people develop ongoing visual disturbances after using psychedelics, a condition called HPPD. Symptoms typically include visual snow, halos around objects, trailing images, or geometric patterns that persist weeks or months after the drug has left your system. The DSM-5 estimates prevalence at about 4.2% of hallucinogen users, though the true number is uncertain because the condition is frequently unrecognized. HPPD is more commonly diagnosed in people with a history of other psychological issues or heavy substance use, but it can occur in anyone, even after a single use.
Dangerous Drug Interactions
Psychedelics interact dangerously with certain psychiatric medications. The most concerning combination involves ayahuasca (which contains natural compounds that block an enzyme called MAO) and antidepressants in the SSRI or SNRI class, including common drugs like fluoxetine, sertraline, and citalopram. This combination can cause serotonin toxicity, a potentially life-threatening condition where excess serotonin floods the nervous system, causing agitation, high fever, rapid heart rate, and muscle rigidity.
Lithium, commonly prescribed for bipolar disorder, is another high-risk combination with psychedelics that has been linked to seizures in case reports. SSRIs taken with psilocybin or LSD (without the MAO-inhibitor component) tend to blunt the psychedelic effect rather than cause toxicity, but the interaction is not fully understood and caution is warranted.
What’s Actually in the Drug Matters
One of the most overlooked risks of psychedelic use comes not from the drugs themselves but from what gets sold in their place. Substances called NBOMes, a class of synthetic hallucinogens, are frequently sold on blotter paper as LSD because they produce similar effects at doses small enough to fit on a tab. In one review of NBOMe poisoning cases, 20% of patients believed they had taken LSD. Two of those patients died, and another attempted suicide. NBOMes are far more physically dangerous than actual LSD, with a much narrower margin between an active dose and a lethal one.
Drug-checking services and reagent test kits can distinguish LSD from NBOMe compounds. If a tab has a noticeably bitter or metallic taste, that’s a warning sign. LSD itself is essentially tasteless.
Context Changes the Risk Dramatically
Clinical trials consistently report far fewer adverse events than surveys of recreational users, and the reason is straightforward: screening, preparation, and environment. In research settings, participants are screened for family history of psychosis and bipolar disorder, they take a known dose of a verified substance, and trained professionals are present throughout. Most of the serious harms documented in the literature involve unsupervised use, unknown substances, dangerous physical environments, or people with unrecognized psychiatric vulnerabilities.
For a healthy person with no family history of psychotic or bipolar disorders, not taking interacting medications, using a verified substance at a known dose in a safe environment, classical psychedelics pose very low physical risk and a modest psychological one. Remove any of those conditions, and the risk profile changes substantially.